Coherus BioSciences, Inc. has made clear its ambitions for the firm’s Udenyca (pegfilgrastim-cbqv) biosimilar, considering the progress towards commercialization for its own proposed on-body injector device that would rival Amgen’s market-leading Neulasta Onpro brand.
“Because of our on-body injector and our position within the pre-filled syringe marketplace, our vision for this brand is to...






